On June 3, 2025, ProQR Therapeutics N.V. held its annual general meeting, with shareholders approving various agenda items including the financial results for 2024 (99.9% approval) and re-appointments of board members ranging from 80.7% to 86.3% approval. The firm also appointed KPMG as external auditor for 2026 (99.8% approval).